Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02419937 · ClinicalTrials.gov registry record · NA
Short-Term Application of Tocilizumab Following Myocardial Infarction
A NA study, sponsored by Keesler Air Force Base Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02419937 is a NA study that has completed, run by Keesler Air Force Base Medical Center. The registered enrollment target is 28 participants.
The verdict
NCT02419937, a NA study, has completed, sponsored by Keesler Air Force Base Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
Introduction: Interleukin 6 (IL-6) is a cytokine that has a pro-inflammatory effect on the immune system. In acute MI IL-6 levels rapidly increase in response to ischemia and inflammation. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). The use of tocilizumab within the first 24 hours of admission for acute MI could reduce 30 day mortality. Methods: This randomized, placebo controlled trial will assign subjects within 24 hours of admission to treatment with either 162 mg of tocilizumab subcutaneously once or placebo in addition to usual pharmacologic and interventional standard of care for acute MI (ST segment elevation MI or non-ST segment elevation MI). Outcomes: The primary outcome is difference in 30 day (plus/minus 5 days) occurrence of major adverse cardiac events (as defined later in this protocol) between placebo and Tocilizumab treated groups. Secondary outcomes to be assessed include length of hospitalization, readmission rates by day 30, CRP levels at 0 hours, 24 hours, 48 hours, and 30 days following treatment, and safety of Tocilizumab with focus on rates of known side effects.
Interventions
- DRUG Placebo
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2015-05 |
| Est. Completion | 2017-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02419937
The ClinicalTrials.gov registry entry for NCT02419937 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Keesler Air Force Base Medical Center, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02419937 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02419937 about?
NCT02419937 is a clinical study titled "Short-Term Application of Tocilizumab Following Myocardial Infarction". Introduction: Interleukin 6 (IL-6) is a cytokine that has a pro-inflammatory effect on the immune system. In acute MI IL-6 levels rapidly increase in response to ischemia and inflammation. Tocilizumab is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). The use of tocilizum...
What is the current status of trial NCT02419937?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2015-05. Estimated completion is 2017-08.
What interventions are being tested in trial NCT02419937?
The interventions under investigation include: Placebo (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT02419937?
This trial is sponsored by Keesler Air Force Base Medical Center, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.